Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Harris Associates Concentrated Strategy. This analysis is provided for institutional research purposes only and is not investment advice.
"Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare and technology leaders."
Harris Oakmark's U.S. Concentrated Strategy returned 3.87% net in Q2 2025, outperforming its benchmark, the Russell 1000 Value Index, which returned 3.79%. Leading contributors for the quarter included Capital One, Charles Schwab, and Alphabet. Key detractors included ConocoPhillips, IQVIA, and Willis Towers Watson. The fund took advantage of market volatility and temporary cyclical headwinds to initiate new positions in Charles River Labs, ICON PLC, and Salesforce. No positions were eliminated. The managers continue to favor a disciplined, bottom-up value approach over index-momentum investing.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Growth Outlook
Market outlook remains above average conviction: Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Risk Appetite
Risk appetite posture is above average conviction: Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Forward Guidance
Forward guidance signal: Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Language Signal
Tone analysis indicates above average conviction language: Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
Time Horizon
Investment time horizon reflects a high conviction orientation. Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare...
